Bimal Shah is the chief operating officer of Homeward, a company focused on improving access to high-quality, affordable comprehensive care in rural communities. Bimal is part of the founding team ...

Dr. Tom Yao has advanced clinical training in neurosurgery, having completed an endovascular neurosurgery fellowship at Vanderbilt University Medical Center in Nashville, Tenn., before joining ...

Syntax Health's new two-sided software-as-a-service solution allows payers and providers (as well as actuaries, network managers and analysts) to collaborate in creating a value-based contract.

CPSI sold American HealthTech — its subsidiary that provides an EHR platform for the post-acute care market — to post-acute health IT vendor PointClickCare. American HealthTech's customers ...

Dr. Paul Komenda is Chief Medical Officer at Quanta, Professor of Medicine at the University of Manitoba, a fellow of the American Society of Nephrology and has extensive clinical and academic ...

Dr. Joseph Clark is a professor of neurology at the University of Cincinnati and the author of My Ambulance Education. He writes regularly at Josephfclark.com.

Ms. Vitti came to ATI Physical Therapy as Chief Executive Officer in 2022 with nearly 30 years of experience in healthcare. Before joining the Company, Ms. Vitti served as Senior Vice President at ...

Providers have been scaling up their tech and IT spend in recent years, increasingly conducting tech pilots to see which solutions can best improve their enterprise’s clinical and operation success.

From left to right: Brenda Schmidt, Head of Strategic Growth and Innovation, Redesign Health; Jim Winkler, Chief Strategy Officer, Business Group on Health; Josh Sturm, Chief Revenue Officer ...

For the past century, heart disease has remained the leading cause of death in the United States. Fortunately, as our understanding of the disease has evolved over time, we have made advances in ...

Organon is broadening its presence in dermatology with a deal to acquire Dermavant, a company whose main asset is a commercialized plaque psoriasis drug that could soon expand its approval to ...

For years, I’ve watched promising medical technologies languish in labs, never reaching the patients who desperately need them. The culprit? Not overzealous regulators, but our antiquated ...